Literature DB >> 9856545

Assessment of acute mountain sickness by different score protocols in the Swiss Alps.

M Maggiorini1, A Müller, D Hofstetter, P Bärtsch, O Oelz.   

Abstract

INTRODUCTION: Purpose of the present study was to evaluate the Lake Louise acute mountain sickness (AMS) score questionnaire at different altitudes and to compare it with the currently used clinical score and the environmental symptoms questionnaire AMS-C score.
METHODS: We investigated 490 climbers who stayed over night at 4 huts in the Swiss Alps, located at the altitudes of 2850 m, 3050 m, 3650 m, and 4559 m. AMS was assessed using our previously described clinical score, the Lake Louise consensus AMS score questionnaire and the environmental symptoms questionnaire III.
RESULTS: Below 4000 m, the prevalence of AMS, defined by symptoms that force a reduction in activity, was 7%; when assessed with the clinical score (score > or = 3) it was 22%; with the AMS-C score (score > or = 0.7) 4% and with the Lake Louise score (score > 4) 8%. At the altitude of 4559 m, the prevalence of AMS was 30%, 38%, 40%, and 39%, respectively. The standardized regression coefficients from multiple regression analysis (adjusted R2 0.65, p < 0.001) were 0.45 (p < 0.001) for the self-reported Lake Louise score, 0.48 (p < 0.001) for the sum of the points assigned in the clinical section of the Lake Louise questionnaire, and 0.05 (p = 0.27) for the AMS-C score. The sensitivity and specificity of the Lake Louise score > 4 was 78% and 93%, respectively.
CONCLUSIONS: The Lake Louise consensus score is adequate and, compared with the AMS-C score, more effective for the assessment of acute altitude illness at different altitudes.

Entities:  

Mesh:

Year:  1998        PMID: 9856545

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  34 in total

1.  High-altitude pulmonary hypertension is associated with a free radical-mediated reduction in pulmonary nitric oxide bioavailability.

Authors:  Damian M Bailey; Christoph Dehnert; Andrew M Luks; Elmar Menold; Christian Castell; Guido Schendler; Vitalie Faoro; Mariusz Gutowski; Kevin A Evans; Sarah Taudorf; Philip E James; J McEneny; Ian S Young; Erik R Swenson; Heimo Mairbäurl; Peter Bärtsch; Marc M Berger
Journal:  J Physiol       Date:  2010-09-27       Impact factor: 5.182

2.  Diagnosis and prediction of the occurrence of acute mountain sickness measuring oxygen saturation--independent of absolute altitude?

Authors:  Veronika Leichtfried; Daniel Basic; Martin Burtscher; Raffaella Matteucci Gothe; Uwe Siebert; Wolfgang Schobersberger
Journal:  Sleep Breath       Date:  2015-06-02       Impact factor: 2.816

3.  Effect of short-term acclimatization to high altitude on sleep and nocturnal breathing.

Authors:  Yvonne Nussbaumer-Ochsner; Justyna Ursprung; Christoph Siebenmann; Marco Maggiorini; Konrad E Bloch
Journal:  Sleep       Date:  2012-03-01       Impact factor: 5.849

4.  Sleep and breathing in high altitude pulmonary edema susceptible subjects at 4,559 meters.

Authors:  Yvonne Nussbaumer-Ochsner; Nicole Schuepfer; Justyna Ursprung; Christoph Siebenmann; Marco Maggiorini; Konrad E Bloch
Journal:  Sleep       Date:  2012-10-01       Impact factor: 5.849

Review 5.  Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.

Authors:  Víctor H Nieto Estrada; Daniel Molano Franco; Roger David Medina; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2017-06-27

6.  Performance at altitude and angiotensin I-converting enzyme genotype.

Authors:  G Tsianos; K I Eleftheriou; E Hawe; L Woolrich; M Watt; I Watt; A Peacock; H Montgomery; S Grant
Journal:  Eur J Appl Physiol       Date:  2004-12-01       Impact factor: 3.078

7.  Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT).

Authors:  Jeffrey H Gertsch; Buddha Basnyat; E William Johnson; Janet Onopa; Peter S Holck
Journal:  BMJ       Date:  2004-03-11

8.  Are nocturnal breathing, sleep, and cognitive performance impaired at moderate altitude (1,630-2,590 m)?

Authors:  Tsogyal D Latshang; Christian M Lo Cascio; Anne-Christin Stöwhas; Mirjam Grimm; Katrin Stadelmann; Noemi Tesler; Peter Achermann; Reto Huber; Malcolm Kohler; Konrad E Bloch
Journal:  Sleep       Date:  2013-12-01       Impact factor: 5.849

9.  The effect of angiotensin-converting enzyme genotype on acute mountain sickness and summit success in trekkers attempting the summit of Mt. Kilimanjaro (5,895 m).

Authors:  Nicholas S Kalson; Julian Thompson; Andrew J Davies; Suzy Stokes; Mark D Earl; Adam Whitehead; Ian Tyrrell-Marsh; Hannah Frost; Hugh Montgomery
Journal:  Eur J Appl Physiol       Date:  2008-11-22       Impact factor: 3.078

10.  The 2018 Lake Louise Acute Mountain Sickness Score.

Authors:  Robert C Roach; Peter H Hackett; Oswald Oelz; Peter Bärtsch; Andrew M Luks; Martin J MacInnis; J Kenneth Baillie
Journal:  High Alt Med Biol       Date:  2018-03-13       Impact factor: 1.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.